Search

everythinglearnresearchcommunity

for

Search:↓

The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.

Individualized treatments may help manage Dercum's disease symptoms.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

The combination therapy was effective and well-tolerated, especially in young patients.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

A rash from semaglutide may be due to propylene glycol, not the drug itself.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Belimumab may cause hair loss in lupus patients.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Dupilumab can cause rare side effects like a rash on the face and neck.

A woman's hair grew back while she was taking sulphasalazine for arthritis.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Topical tacrolimus can effectively treat erosive pustular dermatosis and related hair loss.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Platelet-rich plasma might help treat eczema by reducing inflammation and repairing the skin.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Azathioprine may be an effective treatment for severe hair loss.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

Dupilumab may worsen hair loss in patients with alopecia areata.

Baricitinib improved hair loss and arthritis in a lupus patient.